AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29873894 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 2037
Study 29874098 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISm at phase 1
Number of subjects: 0
Study 29874098 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISm at both phase 1 and phase 2
Number of subjects: 0
Study 29874098 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISm
Number of subjects: 0
Study 29874177 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing of a custom panel of 35 genes (12 for inherited long- and short-QT syndrome genes and 23 additional candidate genes)
Number of subjects: 242
Study 29874177 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional significance examination by patch-clamp electrophysiological recording
Number of subjects: 242
Study 29874546 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 11
Study 29874546 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 11
Study 29875066 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for about 2 years or until disease progression, unacceptable toxicity, patient withdrawal, or investigator decision.
Number of subjects: 104
Study 29875066 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab treatment
Number of subjects: 104
Study 29875084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based decision support tool
Number of subjects: 0
Study 29875084 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal presentation of material
Number of subjects: 0
Study 29875139 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 1605
Study 29876282 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 28
Study 29876358 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Renal Denervation (RDN)
Number of subjects: 13
Study 29876839 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 468
Study 29876839 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 468
Study 29876839 — intervention group
Group type: EXPERIMENTAL
Intervention: One-anastomosis Gastric Bypass (OAGB)
Number of subjects: 468
Study 29876839 — intervention group
Group type: COMPARATOR
Intervention: Control (Preoperative)
Number of subjects: 468
Study 29876999 — intervention group
Group type: EXPERIMENTAL
Intervention: Geophagy during pregnancy
Number of subjects: 552
Study 29876999 — intervention group
Group type: EXPERIMENTAL
Intervention: Geophagy during the third trimester and throughout pregnancy
Number of subjects: 552
Study 29876999 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal geophagy with micronutrient supplementation
Number of subjects: 552
Study 29877131 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A (BOTOX®)
Number of subjects: 10
Study 29877739 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term macrolide therapy for refractory MAC-LD, median duration of treatment 32 months (interquartile range, 24-41 mo)
Number of subjects: 72
Study 29877739 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular analysis of isolates from patients
Number of subjects: 72
Study 29877739 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterial genotyping of stored pre- and post-treatment isolates
Number of subjects: 72
Study 29877768 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral FFA and OFA activity during featural/configural difference judgments
Number of subjects: 0
Study 29877768 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral FFA and OFA activity during distinct exemplar differentiation
Number of subjects: 0
Study 29877768 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of activity within FFA and OFA during chair task
Number of subjects: 0
Study 29877768 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of activity within FFA and OFA during distinct chair exemplar differentiation
Number of subjects: 0
Study 29877990 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Visits (GVs)
Number of subjects: 91
Study 29877990 — intervention group
Group type: COMPARATOR
Intervention: Individual Visits (INDs)
Number of subjects: 91
Study 29878058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) intervention (800 kcal/d) for 8 weeks
Number of subjects: 433
Study 29878058 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified model based on baseline Matsuda index, proline, and phosphatidylcholine 0-34:1
Number of subjects: 433
Study 29878058 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeostasis model assessment of insulin resistance
Number of subjects: 433
Study 29878087 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients failing to recognize symptoms as cardiac
Number of subjects: 3434
Study 29878087 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with rural medical insurance
Number of subjects: 3434
Study 29878087 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with household income of 10,000-50,000 RMB
Number of subjects: 3434
Study 29878087 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with household income of <10,000 RMB
Number of subjects: 3434
Study 29878100 — intervention group
Group type: EXPERIMENTAL
Intervention: JIA patients with TMJ arthritis
Number of subjects: 62
Study 29878653 — intervention group
Group type: EXPERIMENTAL
Intervention: Adeno-associated viral vectors (AAV) gene therapy
Number of subjects: 0
Study 29878653 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of a hyperactive gain-of-function R338L mutation (FIX Padua)
Number of subjects: 0
Study 29878653 — intervention group
Group type: EXPERIMENTAL
Intervention: High vector doses of AAV gene therapy
Number of subjects: 0
Study 29878653 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-editing approaches (ZFN and CRISPR/Cas)
Number of subjects: 0
Study 29878866 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for progressive midgut neuroendocrine tumors (specific intervention details not provided)
Number of subjects: 0
Study 29878989 — intervention group
Group type: EXPERIMENTAL
Intervention: Inframammary fold incision
Number of subjects: 79
Study 29878989 — intervention group
Group type: COMPARATOR
Intervention: Lateral radial incision
Number of subjects: 79
Study 29879010 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbotox technique (154 U)
Number of subjects: 25
Study 29879010 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbotox technique
Number of subjects: 25
Study 29879010 — intervention group
Group type: COMPARATOR
Intervention: Nefertiti technique
Number of subjects: 25
Study 29879010 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 25
Study 29879133 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models using features from enrollment and level 1 treatment (up to week 2 response) of STAR*D
Number of subjects: 0
Study 29879133 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models using top 30 features identified via feature selection
Number of subjects: 0
Study 29879133 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning models using overlapping features between STAR*D and RIS-INT-93
Number of subjects: 0
Study 29879133 — intervention group
Group type: EXPERIMENTAL
Intervention: Early or initial treatment response or symptom severity at week 2
Number of subjects: 0
Study 29879283 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus neoadjuvant chemotherapy (1 dose of panitumumab 2.5 mg/kg followed by 4 cycles of panitumumab 2.5 mg/kg, nab-paclitaxel 100 mg/m2, and carboplatin weekly, then 4 cycles of fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 every 3 weeks)
Number of subjects: 40
Study 29879283 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus neoadjuvant chemotherapy
Number of subjects: 40
Study 29879916 — intervention group
Group type: EXPERIMENTAL
Intervention: Community home-based care intervention
Number of subjects: 682
Study 29880009 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at Guanyuan (CV4), Sanyinjiao (SP6), Taichong (LR3), Zhaohai (KI6) and Qichong (ST30)
Number of subjects: 106
Study 29880009 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at non-acupoints (control group)
Number of subjects: 106
Study 29880049 — intervention group
Group type: EXPERIMENTAL
Intervention: RiseTx web-based intervention with activity tracker (Jawbone), goal of increasing walking by 3000 daily steps over 12 weeks.
Number of subjects: 46
Study 29880049 — intervention group
Group type: EXPERIMENTAL
Intervention: RiseTx web-based intervention
Number of subjects: 46
Study 29880301 — intervention group
Group type: COMPARATOR
Intervention: Standard disinfection (quaternary ammonium disinfectant, except for C difficile, for which 10% hypochlorite was used)
Number of subjects: 314610
Study 29880301 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard disinfection and disinfecting ultraviolet light (UV-C)
Number of subjects: 314610
Study 29880301 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hypochlorite (bleach strategy)
Number of subjects: 314610
Study 29880301 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleach and UV-C (bleach and UV strategy)
Number of subjects: 314610
Study 29880308 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea therapy
Number of subjects: 81
Study 29880467 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based electronic patient-reported outcomes system (ARPEGE)
Number of subjects: 0
Study 29880467 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized validated questionnaires (WHOQOL-HIV BREF)
Number of subjects: 0
Study 29880467 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability testing of the electronic patient-reported outcome system
Number of subjects: 0
Study 29880583 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF inhibitor treatment, specific dosage and duration not mentioned
Number of subjects: 0
Study 29880583 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific treatment not mentioned
Number of subjects: 0
Study 29880603 — intervention group
Group type: EXPERIMENTAL
Intervention: ibrutinib (n=136)
Number of subjects: 269
Study 29880603 — intervention group
Group type: COMPARATOR
Intervention: chlorambucil (n=133)
Number of subjects: 269
Study 29881615 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose ingestion
Number of subjects: 1647
Study 29881615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose ingestion
Number of subjects: 1647
Study 29881616 — intervention group
Group type: COMPARATOR
Intervention: Intervention details not available
Number of subjects: 40
Study 29881622 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMPROBE biopsy
Number of subjects: 30
Study 29881622 — intervention group
Group type: COMPARATOR
Intervention: TRUSBx
Number of subjects: 30
Study 29881627 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal lifestyle intervention programme focusing on nutrition and physical activity
Number of subjects: 0
Study 29881627 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (Control)
Number of subjects: 0
Study 29881956 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine replacement therapy (NRT) 14 or 21 mg per day
Number of subjects: 47
Study 29881956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 29882017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg, single dose) administered after an overnight fast on day 1
Number of subjects: 20
Study 29882017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg) administered with omeprazole (40 mg) on day 7
Number of subjects: 20
Study 29882017 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg) administered alone on days 3-6, 1 hour before breakfast
Number of subjects: 20
Study 29882098 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-Performed Ultrasound (SPUS) for gallstones
Number of subjects: 300
Study 29882098 — intervention group
Group type: COMPARATOR
Intervention: Radiologist-Performed Ultrasound (RPUS) for gallstones
Number of subjects: 300
Study 29882098 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-Performed Ultrasound (SPUS) for acute cholecystitis
Number of subjects: 300
Study 29882098 — intervention group
Group type: COMPARATOR
Intervention: Radiologist-Performed Ultrasound (RPUS) for acute cholecystitis
Number of subjects: 300
Study 29882098 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-Performed Ultrasound (SPUS) for appendicitis
Number of subjects: 300
Study 29882098 — intervention group
Group type: COMPARATOR
Intervention: Radiologist-Performed Ultrasound (RPUS) for appendicitis
Number of subjects: 300
Study 29882481 — intervention group
Group type: EXPERIMENTAL
Intervention: ISC-hpNSC (30 million)
Number of subjects: 12
Study 29882481 — intervention group
Group type: EXPERIMENTAL
Intervention: ISC-hpNSC (50 million)
Number of subjects: 12
Study 29882481 — intervention group
Group type: EXPERIMENTAL
Intervention: ISC-hpNSC (70 million)
Number of subjects: 12
Study 29882693 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physiologic passive knee HE ≥5°
Number of subjects: 1145
Study 29882693 — intervention group
Group type: COMPARATOR
Intervention: No preoperative physiologic passive knee HE ≥5° (non-HE group)
Number of subjects: 1145
Study 29882693 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 1145
Study 29882693 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of allograft
Number of subjects: 1145
Study 29883936 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications
Number of subjects: 0
Study 29883936 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 29884187 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard term infant formula enriched with alpha-lactalbumin, exclusively fed for 6 weeks
Number of subjects: 40
Study 29884204 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 5 CTCs at baseline
Number of subjects: 156
Study 29884204 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 1 CTC cluster at baseline
Number of subjects: 156
Study 29884204 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal evaluation of CTCs and CTC clusters
Number of subjects: 156
Study 29884204 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in CTCs during treatment
Number of subjects: 156
Study 29884204 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline from ≥ 5 CTCs at baseline to < 5 CTCs at 1 month
Number of subjects: 156
Study 29884204 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC clusters presence
Number of subjects: 156
Study 29884204 — intervention group
Group type: COMPARATOR
Intervention: Prognostic model based on clinicopathological variables
Number of subjects: 156
Study 29884223 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotherapy after first Anti-TNF treatment failure
Number of subjects: 0
Study 29884223 — intervention group
Group type: COMPARATOR
Intervention: First Anti-TNF treatment
Number of subjects: 0
Study 29884234 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis Symptom Diary (ESD)
Number of subjects: 272
Study 29884620 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation that terminated persistent AF prior to pulmonary vein isolation
Number of subjects: 55
Study 29884695 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 in a 3+1 schedule
Number of subjects: 1200
Study 29884695 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 in a 3+0 schedule
Number of subjects: 1200
Study 29884695 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 in a 2+1 schedule
Number of subjects: 1200
Study 29884695 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV10 in a two-dose schedule
Number of subjects: 1200
Study 29884695 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13 in a 2+1 schedule
Number of subjects: 1200
Study 29884695 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving two doses of PCV10 at 18 and 24 months
Number of subjects: 1200
Study 29884695 — intervention group
Group type: COMPARATOR
Intervention: Control group of 200 children receiving one dose of PCV10 at 24 months
Number of subjects: 1200
Study 29885373 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged approach with endobronchial ultrasound (EBUS) followed by EMN-bronchoscopy (ENB) and EMN-transthoracic biopsy (EMN-TTNA)
Number of subjects: 150
Study 29885469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 25
Study 29885765 — intervention group
Group type: EXPERIMENTAL
Intervention: Model based on spectral analysis of ventricular fibrillation (VF) ECG tracings
Number of subjects: 0
Study 29885861 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex
Number of subjects: 0
Study 29885885 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) injection intravenously at the end of endometriosis resection.
Number of subjects: 3
Study 29885904 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 5 mg
Number of subjects: 737
Study 29885904 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 737
Study 29885904 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 5 mg
Number of subjects: 737
Study 29885904 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10 mg
Number of subjects: 737
Study 29885904 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 20 mg
Number of subjects: 737
Study 29885989 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 33
Study 29885989 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 33
Study 29886024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor 50 mg or 75 mg orally every 12 hours for 3 days plus one morning (part A) or 24 weeks (part B)
Number of subjects: 26
Study 29886024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor 50 mg orally every 12 hours for 24 weeks (part B)
Number of subjects: 26
Study 29886154 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir (SOF/VEL) 400/100 mg daily for 12 weeks
Number of subjects: 79
Study 29886204 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported anxiety symptoms assessed by the GAD-7 questionnaire in MDD subjects
Number of subjects: 100
Study 29886204 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective cognitive impairment assessed by the Perceived Deficits Questionnaire for Depression-5-item in MDD subjects
Number of subjects: 100
Study 29886204 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported difficulties caused by anxiety in MDD subjects
Number of subjects: 100
Study 29886204 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported difficulties with anxiety in MDD subjects
Number of subjects: 100
Study 29886204 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective cognitive performance assessed by the THINC-it tool in MDD subjects
Number of subjects: 100
Study 29886204 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 100
Study 29886411 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Care (EC) - Standard Care plus cell phone-delivered messaging
Number of subjects: 0
Study 29886411 — intervention group
Group type: COMPARATOR
Intervention: Intensive Care (IC) - Enhanced Care plus cell phone-delivered counselling
Number of subjects: 0
Study 29886411 — intervention group
Group type: COMPARATOR
Intervention: Intensive Care (IC)
Number of subjects: 0
Study 29886411 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Care (SC)
Number of subjects: 0
Study 29886425 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality (Pittsburgh Sleep Quality Index score ≥5)
Number of subjects: 323
Study 29886425 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea risk (Berlin questionnaire)
Number of subjects: 323
Study 29886425 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia (Insomnia Severity Index)
Number of subjects: 323
Study 29886425 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration (actigraphy in subset of n=26)
Number of subjects: 323
Study 29886425 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow-mediated dilation (n=26)
Number of subjects: 323
Study 29886425 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sleep duration
Number of subjects: 323
Study 29886425 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep quality
Number of subjects: 323
Study 29886425 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 323
Study 29886446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fenestration
Number of subjects: 64
Study 29886446 — intervention group
Group type: COMPARATOR
Intervention: Open-release surgery
Number of subjects: 64
Study 29886522 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg (AOM 400)
Number of subjects: 464
Study 29886724 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 478
Study 29888205 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib in combination with best supportive care (BSC)
Number of subjects: 202
Study 29888205 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with best supportive care (BSC)
Number of subjects: 202
Study 29888811 — intervention group
Group type: EXPERIMENTAL
Intervention: PAQ (wearable 3-day insulin delivery device)
Number of subjects: 28
Study 29889229 — intervention group
Group type: EXPERIMENTAL
Intervention: fT3
Number of subjects: 321
Study 29889229 — intervention group
Group type: EXPERIMENTAL
Intervention: fT3/fT4 ratio
Number of subjects: 321
Study 29889229 — intervention group
Group type: COMPARATOR
Intervention: TSH
Number of subjects: 321
Study 29889229 — intervention group
Group type: COMPARATOR
Intervention: fT4
Number of subjects: 321
Study 29889671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-epiglottic space thickness measured with ultrasound (mDSE cut-off value of 2.54 cm)
Number of subjects: 301
Study 29889671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-epiglottic area measured with ultrasound (cut-off value of 5.04 cm)
Number of subjects: 301